This website uses technical, customisation and analytical cookies, both first-party and third-party, to anonymously facilitate browsing and analyse statistics on use of the website. Learn more
HBSP (USA)
-
Celgene
Baker, Malcolm P.; McComb, Emily R.Case HBS-218094-EFinanceIn February 2011, Adam Koppel, a Managing Director at Brookside Capital, the public equity arm of Bain Capital, must decide whether to increase or exit the firm's position in Celgene Corporation. News has emerged that raises potential safety concerns associated with Celgene's key drug, Revlimid. In response, Celgene's share price has traded down 20% in the last two months, and is now almost 10% below the level where Brookside made their initial i...Starting at €8.20
-
Matrix Capital Management (C)
Baker, Malcolm P.; Lane, DavidCase HBS-211060-EFinanceBen Balbale, a partner at hedge fund Matrix Capital, must decide whether to exit their investment in Rovi Corporation, a company with a diverse portfolio of patents used primarily for digital interactive guides. Rovi's shares are up over 50% from the time Balbale initiated a position in the middle of 2009.Starting at €5.74
-
Behavioral Finance at JP Morgan
Baker, Malcolm P.; Sesia, AldoCase HBS-207084-EFinanceFollowing a successful model in Europe, JP Morgan has introduced a set of five U.S. retail mutual funds with an investment philosophy and marketing strategy grounded in behavioral finance. The asset management group believes that understanding investor biStarting at €8.20
-
Modelos multifactoriales
Baker, Malcolm P.Case HBS-209S04FinanceLos estudiantes evalúan el desempeño de los cuatro fondos de inversión y calcular el costo de capital para las empresas que utilizan dos puntos de referencia fijos, el CAPM, y un modelo multifactorial de los retornos.Starting at €8.20
-
Celgene (B)
Baker, Malcolm P.; McComb, Emily R.Case HBS-218099-EFinanceIn February 2011, Adam Koppel, a Managing Director at Brookside Capital, the public equity arm of Bain Capital, must decide whether to increase or exit the firm's position in Celgene Corporation. News has emerged that raises potential safety concerns associated with Celgene's key drug, Revlimid. In response, Celgene's share price has traded down 20% in the last two months, and is now almost 10% below the level where Brookside made their initial i...Starting at €5.74
-
Restructuring JAL, Teaching Note
Baker, Malcolm P.; Sunderam, AdiTeaching Note HBS-215041-EFinanceTeaching note for 214055.Starting at €0.00
-
Longbow Capital Partners
Baker, Malcolm P.; Hanson, Samuel G.; Weber, JamesCase HBS-215026-EFinanceLongbow Capital Partners is a value-oriented long/short hedge fund focused on stocks in the energy sector. In January 2011, Longbow invested in NiSource, a Fortune 500 company that owns a diverse portfolio of regulated energy businesses. In late 2014, Longbow was deciding whether or not to maintain its position in NiSource. To make this decision, students must perform a discounted dividend analysis to determine the fundamental value of NiSource's...Starting at €8.20
-
Matrix Capital Management (A)
Baker, Malcolm P.; Lane, DavidCase HBS-211017-EFinanceBen Balbale, a partner at hedge fund Matrix Capital, must decide whether to exit their investment in Rovi Corporation, a company with a diverse portfolio of patents used primarily for digital interactive guides. Rovi's shares are up over 50% from the time Balbale initiated a position in the middle of 2009.Starting at €8.20
-
Multifactor Models
Baker, Malcolm P.Case HBS-207056-EFinanceStudents evaluate the performance of four mutual funds and compute the cost of capital for two companies using fixed benchmarks, the CAPM, and a multifactor model of returns.Starting at €8.20
-
Behavioral Finance at JP Morgan (Spanish version)
Baker, Malcolm P.; Sesia, AldoCase HBS-209S12FinanceFollowing a successful model in Europe, JP Morgan has introduced a set of five U.S. retail mutual funds with an investment philosophy and marketing strategy grounded in behavioral finance. The asset management group believes that understanding investor biases like overconfidence, anchoring, and loss aversion is key to generating returns on the investment side and educating clients on the advisory side.Starting at €8.20